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Summary:
The role of amifostine in the prevention of cyclophos-
phamide-induced hemorrhagic cystitis (HC) was evalu-
ated in the rat model. Urinary bladders from control
rats that received no drugs (group I) were compared
with those from rats receiving cyclophosphamide alone
at a dose of 150 mg/kg (group II), and two other groups
receiving amifostine at 100 mg/kg (group III) and
200 mg/kg (group IV), 15 min prior to cyclophospham-
ide. Bladders were assessed macroscopically and histo-
logically at 24 h and after 7 days. All the animals that
received cyclophosphamide alone developed severe HC.
On the basis of the scores of macroscopic and histologic
changes, animals that received amifostine showed excel-
lent uroprotection. Only 2/6 rats in group III and 1/6
rats in group IV developed mild HC at 24 h. None of
the rats in either of these groups showed any evidence
of HC at 7 days. It is concluded that amifostine protects
the urothelium against cyclophosphamide-induced HC.
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Hemorrhagic cystitis (HC) is a potentially life-threatening
sequel of therapy with oxazaphosphorine agents
(cyclophosphamide, ifosfamide). It tends to occur most fre-
quently as a consequence of using high-dose cyclophos-
phamide as conditioning therapy for BMT. It has been
noted in 40–50% of these patients and contributes to mor-
tality in 2–4%.1,2 The uro-toxicity of these drugs is related
to contact of the lining epithelium with the renally excreted
4-hydroxy metabolites, particularly acrolein. Other factors
including viral infections, radiation and drugs such as bus-
ulfan may also cause HC in patients undergoing BMT.2
Since there is no effective treatment for this condition,
the emphasis has been on prevention. The most widely
employed method for prevention is the combination of
2-mercaptoethane sodium sulfonate (MESNA) and
hydration.3 This thiol molecule has been shown to bind
acrolein and reduce its toxicity. In spite of this, up to 18%
of patients can develop severe manifestations (grade III to
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grade IV).4 Very recently, the combination of mesna and
hyperbaric oxygen was shown to completely eliminate HC
in guinea pigs.5
Amifostine [S-2-(3-aminopropylamino) ethyl phos-
phorothioic acid], designated WR-2721, is an aminothiol
that is now in clinical use as a protective agent against
chemotherapy-related cytotoxicities.6 Although all the
mechanisms of cytoprotection have not been fully eluci-
dated, the most significant seems to be that the active
metabolite, WR-1065, which is a thiol, acts as an intracellu-
lar scavenger of free radicals.7 Its cytoprotective potential
has been established for various tissues including hemato-
poietic progenitor cells, renal cells, myocardium, intestinal
epithelium and neuronal cells.8,9 The possibility that ami-
fostine may provide protection to the urothelium against
cyclophosphamide-induced HC has not been explored.
In view of the fact that mesna and WR-1065, the active
metabolite of amifostine, are both thiols, we postulated that
amifostine could protect the urothelium against cyclophos-
phamide-induced HC. We evaluated this hypothesis in the
rat model.
Materials and methods
A total of 48 albino rats, weighing 130–270 g, were
allowed free access to food and water and were randomly
assigned to one of four groups of 12 rats each: Group I:
received no drugs at all; group II: received 150 mg/kg of
cyclophosphamide alone by intraperitoneal injection; group
III: received 100 mg/kg of amifostine, 15 min prior to
cyclophosphamide as above; group IV: received 200 mg/kg
of amifostine, 15 min prior to cyclophosphamide as above.
Induction of hemorrhagic cystitis
Cyclophosphamide (150 mg/kg) was administered intraper-
itoneally to consistently induce HC, as previously
described.10
Administration of amifostine
Amifostine was administered intraperitoneally, 15 min
prior to the administration of cyclophosphamide. Two dif-
ferent doses were evaluated – 100 mg/kg (group III) and
200 mg/kg (group IV). These doses were selected on the
basis of previous studies on cytoprotection in rats.11
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Table 1 Comparison of scores on gross evaluation of bladder for
hemorrhage (mean – s.e.m.)
Group Treatment Score day P Score day P
1 value 7 value
I Control 1.0 – 0.0 1.0 – 0.0
II Cyclophosphamide 1.5 – 0.2 2.66 – 0.2
III Af-100 mg/kg and CY 1.0 – 0.0 0.055 1.0 – 0.0 0.001
IV Af-200 mg/kg and CY 1.0 – 0.0 0.055 1.0 – 0.0 0.001
CY = cyclophosphamide; Af = amifostine.
Evaluation of hemorrhagic cystitis
In each group consisting of 12 rats, six were sacrificed 24 h
after treatment and the rest after 7 days using a high intra-
peritoneal injection of 50 mg/kg of pentobarbital. The blad-
ders were carefully dissected and fixed in 10% formalin.
They were macroscopically assessed for HC and graded as
normal (1+), telangiectasia (2+), mucosal hematoma (3+)
and intravesical clots (4+). Standard paraffin blocks were
prepared and sections cut for hematoxylin and eosin-stained
slides. The pathologist evaluating these bladders had no
knowledge of the treatment received by these rats. Histo-
logical damage was graded according to the following cri-
teria: normal histology – normal epithelium, no edema,
inflammatory cell infiltrate, ulceration or hemorrhage (1+);
mild changes – mild edema and inflammation, no hemorrh-
age or ulceration (2+); moderate changes – moderate edema
and inflammation, flattening of epithelium and regener-
ation, focal ulceration and mild hemorrhage (3+); severe
changes – severe edema and inflammation, mucosal
erosions, extensive ulceration and hemorrhage (4+).
Statistical analysis
All numeric data were analyzed using the Wilcoxon rank
sum test.
Results
The scores of gross assessment for presence of hemorrhage
and histologic evaluation of damage to the bladder are
shown in Tables 1 and 2, respectively.
Table 2 Comparison of scores of histologic grading of bladder
changes (mean – s.e.m.)
Group Treatment Score day P Score day P
1 value 7 value
I Control 1.0 – 0.0 1.0 – 0.0
II Cyclophosphamide 3.66 – 0.2 4.0 – 0.0
III Af-100 mg/kg and CY 2.33 – 0.2 0.066 2.0 – 0.0 ,0.001
IV Af-200 mg/kg and CY 2.16 – 0.1 0.003 2.0 – 0.0 ,0.001
CY = cyclophosphamide; Af = amifostine.
Macroscopic assessment
While bladders from animals in group I were normal, HC
was obvious in all animals in group II. It was mild to mod-
erate on the first day but became severe in all by the seventh
day. Bladders from animals in groups III and IV did not
show any evidence of hemorrhage (Table 1).
Histological grading
Bladders of animals in group I were normal (Figure 1). All
the animals in group II (12/12) had evidence of HC. It was
moderate to severe at 24 h (Figure 2a) and uniformly severe
by day 7 (Figure 2b). In group III, only 2/12 animals
showed mild to moderate histological changes of HC (2/6
on day 1 and 0/6 on day 7) (Figure 3a and b). The mean
scores for bladder damage were significantly lower com-
pared to group II (P = 0.006 on day 1 and ,0.001 on day
7). In group IV, only 1/12 animals had mild changes
suggestive of HC (1/6 on day 1 and 0/6 on day 7)
(Figure 4a and 4b) Mild mucosal edema was noted in some
of these bladders. The mean scores for bladder damage
were even lower for this group when compared to group II
(P = 0.003 on day 1 and ,0.001 on day 7).
Discussion
The data presented clearly show that amifostine protects
the urothelium from cyclophosphamide-induced HC.
Though 2/6 animals in the group that received 100 mg/kg
and 1/6 animals in the group that received 200 mg/kg of
amifostine showed mild HC at 24 h, none of the animals
in either group showed any evidence of HC by the seventh
day. How this will translate to clinical protection of patients
from cyclophosphamide-induced HC remains to be estab-
lished, but these results are encouraging. A combination
of mesna and hydration, which is the present standard for
protection against HC, still results in clinically significant
HC in about 20% of patients.4 The recent report of the com-
bination of mesna with hyperbaric oxygen providing com-
plete protection from HC is an excellent experimental
Figure 1 Normal rat bladder. H&E · 40.
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Figure 2 (a) Post-cyclophosphamide treatment – day 1. Extensive ulcer-
ation and severe acute inflammation with hemorrhage and edema. H&E
· 40. (b) Post-cyclophosphamide treatment – day 7. Marked edema with
extensive hemorrhage and inflammation. H&E · 90.
model,5 but it is not practical for the majority of patients
undergoing chemotherapy or BMT.12
The metabolites of cyclophosphamide are urotoxic and
may persist in blood for 12–24 h after a single dose.13
Mesna exerts its protective effect by binding with these
toxic metabolites in the lumen of the urinary system. Since
the half-life of mesna is very short, multiple doses are
required for continued neutralization of these metabolites.
It is likely that this mechanism does not completely prevent
exposure of the urothelium to acrolein and other toxic
metabolites. This would explain the occurrence of HC in
some patients in spite of mesna.4 Recent pharmacokinetic
studies have shown that amifostine has a biphasic decrease
in levels after intravenous administration with a final half-
life of 0.8 h.14 Its active metabolite, WR-1065, however,
has a much longer plasma half-life of 7.3 – 3.6 h. It is pos-
sible that the intracellular WR-1065 may persist for even
longer in normal tissues because a single dose of amifostine
Figure 3 (a) Cyclophosphamide and amifostine (100 mg/kg) treated
bladders – day 1. Marked edema with mild inflammation, congestion and
focal ulceration. H&E · 40. (b) Cyclophosphamide and amifostine
(100 mg/kg) treated bladders – day 7. Mild edema, congestion and
inflammation. H&E · 40.
appears to protect from both early and late (.48 h) HC.
This could be the basis for continued and more effective
protection of the urothelium until the disappearance of all
metabolites of cyclophosphamide.
If clinical trials are to be initiated based on these data,
then issues related to the dose and route of administration
of amifostine need to be considered. The dose range of
100–200 mg/kg was used in this study because most of the
pre-clinical data on cytoprotection of tissues by amifostine
in mice and rats are based on doses ranging from 100–
400 mg/kg.15 The dose of 200 mg/kg in rats is equivalent
to about 1180 mg/m2.11 The ideal dose of amifostine for
different clinical situations remains to be defined, but doses
of 740 mg/m2 or 910 mg/m2 have been shown to provide
cytoprotection in most studies.4 It would be reasonable to
presume that protective levels could be attained in the uro-
thelium with these doses. Pharmacokinetic studies in mice
show that peak blood levels are achieved 5 min after intra-
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Figure 4 (a) Cyclophosphamide and amifostine (200 mg/kg) treated
bladders – day 1. Mild edema and congestion. H&E · 40. (b) Cyclophos-
phamide and amifostine (200 mg/kg) treated bladders – day 7. Minimal
edema and congestion. H&E · 40.
peritoneal administration of amifostine followed by a 10-
fold reduction in 30 min.16 Peak tissue concentrations were
observed 10–30 min after administration. This is similar to
the pharmacokinetics of amifostine observed after intra-
venous administration.14 Therefore, clinical trials to assess
urothelial cytoprotection against oxazaphosphorine drugs
should be possible using amifostine at standard dosage,
watching carefully for the frequent side-effects of mild
transient hypotension and emesis.17 The fact that amifostine
protects all normal cells from chemotherapy and radiation,
precludes its use in allogeneic BMT.
Apart from preventing HC, there could be another advan-
tage of using amifostine in this situation. The use of oxaza-
phosphorine drugs is associated with mutagenesis and blad-
der cancers, particularly in those patients who develop
cystitis.18,19 Amifostine has been shown to prevent drug-
induced mutagenesis.20 It is therefore possible that when
used in conjunction with cyclophosphamide and ifosfam-
ide, it may not only provide immediate protection from HC
but also prevent mutagenesis and evolution of secondary
malignancies.
In conclusion, this study demonstrates the uroprotective
effects of amifostine against cyclophosphamide-induced
HC in rats. This will require confirmation in clinical trials.
It could then be used for uroprotection in patients receiving
high-dose cyclophosphamide and ifosfamide as part of their
chemotherapy or conditioning regimen for autologous stem
cell transplantation.
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